Loading...
XCSE
AMBUb
Market cap2.81bUSD
Jul 22, Last price  
69.25DKK
1D
-0.57%
1Q
4.69%
Jan 2017
22.13%
Name

Ambu A/S

Chart & performance

D1W1MN
XCSE:AMBUb chart
P/E
30.22
P/S
3.05
EPS
2.29
Div yield, %
0.59%
Shrs. gr., 5y
1.49%
Rev. gr., 5y
11.10%
Revenues
6.04b
+11.98%
715,861,000715,024,000784,445,000876,931,000939,688,000982,812,0001,045,457,0001,383,000,0001,584,000,0001,889,000,0002,084,000,0002,355,000,0002,606,000,0002,820,000,0003,567,000,0004,013,000,0004,444,000,0004,775,000,0005,391,000,0006,037,000,000
Net income
609m
+159.15%
48,415,00042,777,00050,011,00055,764,00084,055,00069,213,000114,713,00048,000,000151,000,000152,000,000250,000,000301,000,000337,000,000317,000,000241,000,000247,000,00093,000,000168,000,000235,000,000609,000,000
CFO
791m
-2.71%
98,442,00088,306,00084,465,000113,015,00098,655,000102,071,000157,625,000122,000,000183,000,000208,000,000369,000,000462,000,000554,000,000533,000,000295,000,000328,000,00095,000,000518,000,000813,000,000791,000,000
Dividend
Dec 04, 20250.41 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics segmet provides electrodes for cardiology, neurophysiology, and polysomnography. The Visualisation segment includes single-use visualisation devices, which are used in single lung ventilation procedure, or a bedside bronchoscopy procedure in the intensive care unit . The company was founded by Holger Hesse in 1937 and is headquartered in Ballerup, Denmark.
IPO date
Mar 09, 1992
Employees
4,500
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT